Hypoxia-targeted Intensification of Radiotherapy for Bladder Preservation: A Phase III Randomised Trial of Biomarker Validation (CONCeRT)

We are developing a trial to investigate whether the addition of hypoxia modification using carbogen and nicotinamide (CON) can improve response to chemoradiotherapy for patients with muscle invasive bladder cancer (MIBC). 

We are submitting a funding application to CRUK and we are seeking registrations of interest and feedback on the trial from UK oncologists to support our application.

Approximately 540 participants will be included in this phase III randomised controlled trial comparing chemoradiotherapy + CON with chemoradiotherapy alone. Routinely obtained diagnostic tissue will be centrally collected for prospective hypoxia-biomarker testing. The primary endpoint is two year loco-regional recurrence control.

More details can be found in the trial synopsis.

To register interest or provide feedback, please complete the short survey linked below or email [email protected].

CONCeRT trial expression of interest